Skip to main content
Clinical Trials/NCT00845598
NCT00845598WithdrawnPhase 4

A Proof of Concept Study to Evaluate Comparative Efficacy of an Azelastine/Fluticasone Combination Nasal Spray vs. Twice the Dose of Fluticasone in Persistent Allergic Rhinitis

University of Dundee2 sites in 1 countryStarted: August 2010Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Withdrawn
Locations
2
Primary Endpoint
Maximum percentage fall in PNIF after 400mg/ml of AMP nasal challenge between both groups.

Study Overview

Brief Summary

The purpose of this study is to see how a combination spray of azelastine and fluticasone (antihistamine and steroid) compares with a steroid nasal spray (fluticasone) alone in allergic rhinitis i.e. does azelastine permit the use of lesser steroid dose (steroid sparing effect) to achieve the same benefit.

Detailed Description

Allergic rhinitis (AR) is a major chronic respiratory disease with a prevalence approaching nearly 25% in the worldwide population.Allergic Rhinitis is a common and relatively undiagnosed public health problem and has been reported as being one of the ten most common causes for outpatient attendances to the general practitioner. Long term untreated allergic rhinitis may lead on to asthma. When exposed to allergens (pollen, house dust mite etc) in the atmosphere, the mast cells in the nose burst and an inflammatory response is triggered and patients experience sneezing, itching, blocked nose and running. These allergens may be used as provocation agents to recreate the disease symptoms to confirm the diagnosis of which allergens one is allergic to. However, there is a risk of allergic reactions in doing so. Adenosine monophosphate (AMP)achieves the same goal by stimulating the mast cells and causing them to burst without actually the risks of allergen provocation tests. Such tests are now commonplace in research and clinical medicine. Nasal steroids are considered to be the most potent medications for allergic rhinitis, particularly nasal blockage. Nasal antihistamines are also available but they act mainly to limit nasal running, itching and sneezing and have lesser effect on blockage. The other advantage is that they act very quickly while steroids take at least 72 hours to begin acting and weeks to achieve maximal benefit. Finally, they are free of significant short and long term side effects. Having said that nasal steroids are very safe and unlike inhaled or oral steroids have not been shown to cause systemic side effects in adults. Therefore, it is interesting to see if a combination of an antihistamine and nasal steroid would add their good qualities mentioned above and by the act of reducing the dose of steroid reduce their side effects. To do this we will use nasal AMP challenge as an outcome measure as we have done research studies for over a decade with. We will look at noninvasive nasal airflow parameters, nasal nitric oxide levels, and for safety we will look at the overnight urinary cortisol and creatinine ratio which is the most sensitive and noninvasive test of urine to quantify how much steroid has been absorbed in the blood stream.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Male of Female aged 18-65 years.
  • Persistent allergic rhinitis with or without asthma.
  • Atopy to at least one allergen on SPT.
  • Ability to give a written informed consent.
  • Ability and willingness to comply with the requirements of the protocol.

Exclusion Criteria

  • Recent respiratory tract/sinus infection within the last 2 months. .
  • Pregnancy, planned pregnancy or lactation.
  • Known or suspected hypersensitivity to any of the IMP's.
  • Concomitant use of medicines (prescribed, OTC or herbal) like alpha blockers that may interfere with the trial.
  • Nasal Polyposis grade 2+, Deviated nasal septum ≥ 50%
  • The use of oral corticosteroids within the last 3 months.

Arms & Interventions

Azelastine Fluticasone

Experimental

Intervention: Azelastine , fluticasone (Drug)

Fluticasone propionate

Active Comparator

Intervention: Fluticasone propionate (Drug)

Outcomes

Primary Outcomes

Maximum percentage fall in PNIF after 400mg/ml of AMP nasal challenge between both groups.

Time Frame: 0, 2 weeks, 4 weeks, 6 weeks, 8 weeks

Secondary Outcomes

  • Overnight urinary cortisol creatinine ratio(0, 2 weeks, 4 weeks, 6 weeks, 8 weeks)
  • Domiciliary diary cards(2 week treatment periods)
  • 60 minute recovery to AMP challenge(0, 2 weeks, 4 weeks, 6 weeks, 8 weeks)
  • Mini RQLQ(0, 2 weeks, 4 weeks, 6 weeks, 8 weeks)
  • Global visual analogue scale(0, 2 weeks, 4 weeks, 6 weeks, 8 weeks)
  • Nasal lavage for cytokines(0, 2 weeks, 4 weeks, 6 weeks, 8 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Brian J Lipworth

Professor

University of Dundee

Study Sites (2)

Loading locations...

Similar Trials